

Saurabh Zanwar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/35850/publications.pdf>

Version: 2024-02-01

60
papers

625
citations

858243

12
h-index

759306

22
g-index

61
all docs

61
docs citations

61
times ranked

967
citing authors

#	ARTICLE	IF	CITATIONS
1	Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. American Journal of Hematology, 2022, 97, 151-159.	2.0	0
2	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	3.3	12
3	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	2.5	4
4	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. Therapeutic Advances in Hematology, 2022, 13, 204062072210939.	1.1	4
5	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 2022, 12, .	2.8	7
6	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
7	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
8	66-Year-Old Man With Recurrent Hypotension and Flank Pain. Mayo Clinic Proceedings, 2021, 96, 1622-1627.	1.4	0
9	Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3087-3097.	0.6	5
10	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
11	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	2.8	9
12	Poster: MM-429: Impact of Prolonged Lenalidomide Maintenance (≥3 years) and Outcomes in Patients with Multiple Myeloma Post-Autologous Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S252.	0.2	0
13	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	1.7	11
14	Epidermal growth factor receptor mutated lung cancers: Looking beyond adenocarcinomas. Indian Journal of Cancer, 2021, 58, 3.	0.2	1
15	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	0.6	1
16	High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. Blood, 2021, 138, 2526-2526.	0.6	1
17	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	0.6	0
18	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1439-1439.	0.6	0

#	ARTICLE	IF	CITATIONS
19	BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics. <i>Blood</i> , 2021, 138, 2582-2582.	0.6	1
20	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
21	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
22	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
23	Immune-based therapies in the management of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 84.	2.8	38
24	Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 31-43.	1.2	9
25	Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 45-55.	1.2	10
26	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
27	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
28	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	0.8	65
29	Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2599-2601.	0.6	0
30	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 70-82.	1.2	16
31	Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e38-e39.	0.2	0
32	Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13017.	0.7	20
33	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
34	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
35	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenström macroglobulinemia (WM). <i>Journal of Clinical Oncology</i> , 2019, 37, 7509-7509.	0.8	4
36	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study. <i>Journal of Clinical Oncology</i> , 2019, 37, 7559-7559.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Current Therapeutic Options in Waldenström Macroglobulinemia. <i>Oncology & Hematology Review</i> , 2019, 15, 39.	0.2	0
38	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
39	Ixazomib: a novel drug for multiple myeloma. <i>Expert Review of Hematology</i> , 2018, 11, 761-771.	1.0	19
40	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
41	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. <i>Indian Journal of Medical Research</i> , 2018, 148, 284.	0.4	5
42	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018, 132, 1912-1912.	0.6	0
43	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	0.6	1
44	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
45	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
46	A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 100-102.	0.6	4
47	EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1859-1863.	1.0	44
48	Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients. <i>Indian Journal of Cancer</i> , 2017, 54, 280.	0.2	8
49	Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. <i>Indian Journal of Cancer</i> , 2017, 54, 678.	0.2	6
50	Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20628-e20628.	0.8	1
51	Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 958-967.	0.6	10
52	Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). <i>International Journal of Surgical Oncology</i> , 2016, 2016, 1-8.	0.3	18
53	Rectal GIST“Outcomes and viewpoint from a tertiary cancer center. <i>Indian Journal of Gastroenterology</i> , 2016, 35, 445-449.	0.7	7
54	EGFR mutation in squamous cell carcinoma of lung - Does it carry the same connotation as in adenocarcinomas?. <i>Annals of Oncology</i> , 2016, 27, vi431.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Impact of Surveillance Stool Culture Guided Selection of Antibiotics in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2016, 128, 3389-3389.	0.6	3
56	Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India. <i>Indian Journal of Cancer</i> , 2016, 53, 313.	0.2	10
57	Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. <i>South Asian Journal of Cancer</i> , 2016, 05, 182-185.	0.2	12
58	Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis. <i>Indian Journal of Cancer</i> , 2016, 53, 579.	0.2	3
59	Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. <i>Annals of Translational Medicine</i> , 2016, 4, 74.	0.7	6
60	Use of Antibiotic Lock for Salvage of Tunneled Central Venous Catheters with Catheter Colonisation and Catheter Related Blood Stream Infection in a Tertiary Care Hematopoietic Stem Cell Transplantation Unit- a Strategy Revisited. <i>Blood</i> , 2015, 126, 3116-3116.	0.6	0